52 Week Range
As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay
Nov 5 (Reuters) - BioCryst Pharmaceuticals Inc <BCRX.O>::BIOCRYST ANNOUNCES PARTNERSHIP WITH TORII PHARMACEUTICAL TO COMMERCIALIZE BCX7353 IN JAPAN FOR THE PREVENTION OF HAE ATTACKS.BIOCRYST PHARMACEUTICALS- WILL RECEIVE $22 MILLION UPFRONT PAYMENT AND IS ELIGIBLE TO RECEIVE UP TO AN ADDITIONAL $20 MILLION UPON ACHIEVEMENT OF CERTAIN MILESTONES.BIOCRYST PHARMACEUTICALS - BIOCRYST WILL RECEIVE TIERED ROYALTIES RANGING FROM MID-TEENS TO POTENTIALLY 40 PERCENT OF JAPANESE NET SALES OF BCX7353.
Japan Tobacco Inc <2914.T>::JAPAN TOBACCO INC - TRANSFER DATE OF MARKETING APPROVALS OF 6 ANTI-HIV DRUGS TO GILEAD SCIENCES KK SET FOR DEC. 1.
July 12 (Reuters) - Japan Tobacco Inc <2914.T>::TOP-LINE RESULTS OF PHASE 3 CLINICAL STUDIES OF JTZ-951 IN ANEMIC PATIENTS WITH CHRONIC KIDNEY DISEASE IN JAPAN.RESULTS SHOW BOTH STUDIES MET PRIMARY ENDPOINTS.JT AND TORII <<<4551.T>>> WILL AIM TO SUBMIT MARKETING APPLICATION FOR JTZ-951 IN JAPAN BASED ON RESULTS OF THIS AND OTHER CLINICAL STUDIES.
Torii Pharmaceutical Co Ltd <4551.T>::GOICHI MATSUDA TO BE PRESIDENT EFFECTIVE MARCH 26.
Sept 27 (Reuters) - Torii Pharmaceutical Co Ltd <4551.T>:* Says the Japanese Ministry of Health, Labour and Welfare has approved the new drug application of "CEDARCURE® Japanese Cedar Pollen Sublingual Tablets", an allergen immunotherapy tablet for Japanese cedar pollinosis .
Menlo Therapeutics Inc : Menlo Therapeutics signs exclusive license agreement with Japan Tobacco and Torii Pharmaceuticals for development and commercialization of NK-1 receptor antagonist in Japan . Entered into license agreement with Japan Tobacco Inc. and Torii Pharmaceutical for development,commercialization of serlopitant in Japan .JT,Torii to pay co upfront licensing fees,payments upon achievement of certain milestones, royalties based on future sales in Japan.
Torii Pharmaceutical Co Ltd:Says the company increased the consolidated full-year outlook for revenue to 62,370 mln yen from 61,300 mln yen, for the fiscal year ending Dec. 31, 2015.Operating profit forecast increased to 4,910 mln yen from 4,000 mln yen.Ordinary profit forecast increased to 5,130 mln yen from 4,200 mln yen.Net profit forecast increased to 3,520 mln yen from 2,600 mln yen.Earnings per share increased to 124.38 yen from 91.87 yen.Comments the increased sales of core products and cost control are the main reasons for the forecast.
Torii Pharmaceutical Co Ltd:Filed a New Drug Application for TO-206, an allergen immunotherapy tablet for Japanese cedar pollinosis to the Japanese Ministry of Health, Labour and Welfare.
Torii Pharmaceutical Co Ltd:Obtained the marketing approval of MITICURE® House Dust Mite Sublingual Tablets (“MITICURE” hereinafter), an allergen immunotherapy tablet for house dust mite allergy, for the indication of allergic rhinitis. in Japan.
Japan Tobacco Inc:Signed an exclusive distribution agreement in Japan of 2 new anti-HIV drugs with Torii Pharmaceutical Co., Ltd.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.